Biohaven Pharmaceutical (NYSE:BHVN)‘s stock had its “buy” rating reissued by Canaccord Genuity in a note issued to investors on Thursday. They presently have a $39.00 target price on the stock, up from their previous target price of $30.00. Canaccord Genuity’s price objective suggests a potential upside of 17.82% from the company’s previous close.
BHVN has been the topic of several other research reports. Zacks Investment Research lowered shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. BidaskClub lowered shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, October 27th. Piper Jaffray Companies set a $48.00 target price on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Monday, December 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $36.00 target price on shares of Biohaven Pharmaceutical in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $37.43.
Biohaven Pharmaceutical (BHVN) opened at $33.10 on Thursday. The stock has a market cap of $1,190.00 and a price-to-earnings ratio of -6.34. Biohaven Pharmaceutical has a fifty-two week low of $17.00 and a fifty-two week high of $39.51.
In other news, CFO James Engelhart sold 10,000 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $32.50, for a total transaction of $325,000.00. Following the transaction, the chief financial officer now owns 13,576 shares in the company, valued at $441,220. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Kimberly Gentile sold 5,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $21.99, for a total transaction of $109,950.00. The disclosure for this sale can be found here. Insiders have sold 858,546 shares of company stock worth $24,219,162 in the last quarter.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in shares of Biohaven Pharmaceutical during the third quarter valued at about $119,000. Deutsche Bank AG raised its holdings in shares of Biohaven Pharmaceutical by 28.6% during the fourth quarter. Deutsche Bank AG now owns 23,580 shares of the company’s stock valued at $635,000 after purchasing an additional 5,248 shares during the period. Nationwide Fund Advisors acquired a new position in shares of Biohaven Pharmaceutical during the third quarter valued at about $214,000. American International Group Inc. acquired a new position in shares of Biohaven Pharmaceutical during the third quarter valued at about $251,000. Finally, State of Wisconsin Investment Board acquired a new position in shares of Biohaven Pharmaceutical during the third quarter valued at about $262,000. Hedge funds and other institutional investors own 52.82% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Biohaven Pharmaceutical (BHVN) Stock Rating Reaffirmed by Canaccord Genuity” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/24/biohaven-pharmaceutical-bhvn-stock-rating-reaffirmed-by-canaccord-genuity.html.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.